AstraZeneca Stock Looks Undervalued on Cash Flow Alongside Two UK Shares

With inflation, interest rates and energy costs all pulling on markets, many investors are looking for stocks where the cash story looks stronger than the share price. That is exactly what the Undervalued Stocks Based On Cash Flows screener targets, highlighting companies that SWS DCF valuation suggests are trading below their estimated fair value. By focusing on cash flow potential instead of headlines alone, the theme aims to surface opportunities across sectors that may suit patient, value-oriented investors. In this article, you will see three stocks currently highlighted by this screener.

Living REIT (LSE:LIVE)

Overview: Living REIT is a UK based real estate investment trust that owns and manages a portfolio of social housing, aiming to provide shareholders with income from rent on social homes, with the potential for long term capital growth.

Operations: Living REIT generates around £40.8 million in revenue from its residential REIT activities, all from properties in the United Kingdom.

Market Cap: £310.8 million

Living REIT may catch your eye because SWS DCF work suggests the stock trades well below its estimated cash flow value. It is now profitable and analysts expect solid earnings and revenue growth over the next few years. At the same time, the company carries higher risk funding, a history of earnings volatility due to one off items and a very high P/E multiple that may concern valuation focused investors. In addition, it has a progressive dividend policy, a refreshed board and new debt facilities that shape its interest cost profile. Overall, this is a social housing REIT where the balance between income potential and balance sheet risk may deserve a closer look.

Living REIT’s share price story and its cash flow valuation are pulling in different directions. The next step is to see what that gap might really mean through the DCF valuation analysis for Living REIT

AstraZeneca (LSE:AZN)

Overview: AstraZeneca is a global biopharmaceutical company that discovers, develops, manufactures and sells prescription medicines across oncology, cardiovascular and metabolic disease, respiratory and immunology, vaccines and rare diseases, serving doctors and patients worldwide.

Operations: AstraZeneca generates about US$60.4b in revenue from its pharmaceuticals portfolio.

Market Cap: £197.0b

AstraZeneca stands out for investors because it combines a broad portfolio of high-demand medicines with a deep late stage pipeline in areas like oncology and rare diseases. Earnings growth has recently outpaced both the UK market and the wider pharmaceuticals sector. Simply Wall St’s cash flow work indicates the stock trades well below estimated fair value, and analysts, including recent buyers such as Oakmark Global Fund, see further potential if key drug launches and approvals continue to land. On the other hand, there is meaningful risk from high R&D spend, heavy reliance on blockbuster drugs that face future patent and pricing pressure, and fresh regulatory or trial setbacks such as the Wainua Phase III result. Taken together, these factors make the AstraZeneca story more nuanced than the headline multiples alone suggest.

AstraZeneca’s earnings trajectory and pipeline progress are starting to decouple from the current share price, and the real question is what the detailed analyst forecasts for AstraZeneca quietly signals about the next wave of risk and reward

Foresight Group Holdings (LSE:FSG)

Overview: Foresight Group Holdings is a London based asset manager that runs infrastructure, private equity, venture capital and listed funds, with a focus on renewable energy, social and digital infrastructure, and sustainable real assets for institutional and retail investors across several regions.

Operations: Foresight Group Holdings generates about £114.8 million from Real Assets and £50.1 million from Private Equity, with most revenue coming from the United Kingdom and Australia.

Market Cap: £525.3 million

Foresight Group Holdings is attracting attention because it combines fast growing fee earning assets with high quality profitability, including net margins around 27.7% and return on equity that analysts expect to reach very high levels. Recent full year results show revenue of £164.92 million and net income of £42.83 million, while ongoing share buybacks are shrinking the free float and can amplify earnings per share over time. On the flip side, the business leans heavily on UK and European infrastructure and renewables policy, relies on performance fees and uses higher risk external borrowing. Any policy shifts or weaker fund performance could therefore have a negative impact. The key issue for investors is how these strengths and pressure points balance out as the AUM story develops.

Foresight Group Holdings has fee revenue and margins that look strong, but the real story sits in how future earnings could scale from here. Get the full analyst forecasts for Foresight Group Holdings and see what the current share price might be missing.

The three stocks covered here are only a starting point. The full Undervalued Stocks Based On Cash Flows screener surfaces 37 more companies where cash flow potential and current pricing tell equally compelling stories. Use Simply Wall St to identify and analyze the specific catalysts and narratives that matter most to you so you can focus on the highest conviction opportunities in this cash flow focused idea.

Take Control of Your Investment Journey

If Foresight Group Holdings or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives For Your Curiosity?

Fresh ideas do not stay under the radar for long, and once momentum builds, ideal entry points can pass by before the crowd reacts, so consider acting early.

• Spot potential income opportunities by scanning companies in the 5 dividend fortresses that aim to keep paying while others are dropping behind.
• Track where earnings momentum may be building by reviewing the curated 64 profitable AI stocks that aren't just burning cash before these cash generators are fully noticed by the crowd.
• Hunt for resilient balance sheets that could withstand shocks with the hand picked list of solid balance sheet and fundamentals (21 results) while that information edge still matters.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com